ProQR Therapeutics (NASDAQ:PRQR) Receives Buy Rating from Chardan Capital
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $4.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s target price suggests a potential upside of 136.69% from the stock’s previous close. PRQR […]
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $4.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s target price suggests a potential upside of 136.69% from the stock’s previous close. PRQR […]
